Second-line TAT after targeted beta therapy. Two patients with low-grade oligodendroglioma, who were initially treated with [90Y]Y-DOTA-substance P, developed a tumor relapse 11 and 9 years following initial beta therapy, which was treated with TAT. The gene discussed is TAC1; the disease is neoplasm.